A wide-range of cancer types have been identified as liquid tumors that occur in the blood, bone marrow and lymph nodes. One such type, Lymphoma, is a cancer of the lymphatic system, which is part of the body's germ-fighting network. Reproducible and time-efficient criteria based on FDG-PET imaging has led to improved clinical outcomes in the development of new cancer therapies for FDG-avid lymphoma.
During this webinar the panel of experts will review:
Speaker information below.
Ms. Ferreira leads a group of expert Clinical Trialists who specialize in response criteria and clinical trial design at Merigold LLC. She has 16+ years of experience in the imaging space and expertise in the implementation of response criteria. Her day-to-day focus is logical thinking, clear communication and simplifying complex concepts.
Ms. Gillis is a Clinical Trialist at Merigold LLC with a background in nuclear imaging and public health. She is a response criteria expert with 15+ years of practical experience incorporating lymphoma response criteria into clinical trial designs. Her lymphoma experience spans evolving treatment types and response criteria.
Dr. Montgomery holds two medical degrees, one from the Superior School of Health Sciences, Brazil and another from the University of Porto, Portugal. She completed her residency in Radiology and earned a Ph.D. from the University of Utrecht (Netherlands) in breast cancer imaging.
Dr. Montgomery has seven years of national and international experience in breast cancer imaging clinical trials phases I-IV, and published several scientific peer-reviewed manuscripts in journals, such as Radiology and European Radiology, as first author. She has expertise in protocol design, statistical analysis, imaging evaluation, regulatory affairs, artificial intelligence and business development.